Adam JacksonFebruary 6, 2023
MDMA and psilocybin used for therapy will be reclassified by July 1, 2023.
Tag: MDMA
Adam JacksonFebruary 6, 2023
Debra BorchardtFebruary 6, 2023
PharmaAla to supply the MDMA.
Dave HodesFebruary 1, 2023
Can psychedelics really treat the wide range of conditions being considered?
Dave HodesNovember 30, 2022
Researchers looking more closely at similarities of compounds and responses.
Adam JacksonSeptember 15, 2022
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) posted positive results as revenue rose along with patients — showing the growing demand for psychedelics-centered therapy to treat addictions. The Canadian biotechnology company released its financial report card for the second quarter ending July 31. Awakn posted revenues of C$339,872 via Awakn’s clinics for the second […]
Dave HodesMay 6, 2022
MDMA, or methylenedioxymethamphetamine, has become more of a psychedelics wonder drug today, distancing itself as the rave party fuel (ecstasy or Molly) that it was in the 1980s and being positioned as the wonder drug that psychedelics researchers have hoped for. Researchers have discovered that MDMA, with structural similarities to both mescaline and methamphetamine, can […]
Dave HodesApril 14, 2022
Public funding for new mental health discoveries that can change the lives of millions of Americans for good? In a word: Absolutely. Over the last three years, clinical trials of psilocybin and MDMA psychedelics assisted therapy in particular have demonstrated their value in treating various mental health conditions, even hard to treat conditions such as […]
Julie AitchesonMay 5, 2021The Multidisciplinary Association of Psychedelic Studies (MAPS) has worked for the last 35 years to shift the perception around psychedelics as a treatment tool for mental health issues. Now, with the release of data from its Phase III trial with the FDA for the use of MDMA (ecstasy) to treat PTSD, MAPS’ work has coalesced […]
StaffOctober 15, 2020A peer-reviewed study published in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when compared to currently available treatments for posttraumatic stress disorder (PTSD). It is estimated that a public healthcare payer or private insurer making MDMA-assisted psychotherapy available to 1,000 patients with PTSD would reduce general and mental health care costs by $103.2 million over 30 years. This treatment has not yet been […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.